'Timi major' diaporamas de présentation

Progress in Oral Anti-Platelet Therapy

Progress in Oral Anti-Platelet Therapy. Rabih R. Azar, MD, MSc, FACC Division of Cardiology Hotel Dieu de France Hospital. GP IIb/IIIa Receptor Activation Pathway. ADP. Thrombin. TXA 2. PAF. PLATELET. ASPIRIN. Vasopressin. Epi. ASPIRIN. ASPIRIN. HEPARINS. ASPIRIN. CLOPIDOGREL.

765 views • 50 slides

563 views • 38 slides

448 views • 35 slides

The Landscape of Oral Antiplatelet Agents 2009

The Landscape of Oral Antiplatelet Agents 2009. George D. Dangas, MD, PhD, FSCAI, FACC Associate Professor of Medicine Columbia University Medical Center. Disclosures. Advisory Board: Accumetrics, Astra-Zeneca Consultant: Lilly, Daichi-Sankyo Speaker honoraria: Sanofi-Aventis, BMS. 33% ?

284 views • 26 slides

TIMI

219 views • 20 slides

Disclosure

PCI in Patients Receiving Enoxaparin or UFH Following Fibrinolytic Therapy for STEMI: PCI ExTRACT-TIMI 25.

337 views • 18 slides

SYNERGY PCI A Subset analysis of the SYNERGY trial

SYNERGY PCI A Subset analysis of the SYNERGY trial. 4,687 high-risk ACS patients undergoing PCI after randomization to unfractionated heparin or enoxaparin. Enoxaparin 1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose.

245 views • 4 slides

Montalescot et al. NEJM 2013

ACCOAST: no difference in efficacy endpoint between pretreatment with prasugrel or no pretreatment. Montalescot et al. NEJM 2013. ACCOAST: All TIMI major bleeding after pretreatment with prasugrel or no pretreatment. Montalescot et al. NEJM 2013.

170 views • 2 slides